The study of hepatitis C virus (HCV), a major cause of chronic liver disease, has been hampered by the lack of a cell culture system supporting its replication. Here, we have successfully generated infectious pseudo-particles that were assembled by displaying unmodified and functional HCV glycoproteins onto retroviral and lentiviral core particles. The presence of a green fluorescent protein marker gene packaged within these HCV pseudo-particles allowed reliable and fast determination of infectivity mediated by the HCV glycoproteins. Primary hepatocytes as well as hepato-carcinoma cells were found to be the major targets of infection in vitro. High infectivity of the pseudo-particles required both E1 and E2 HCV glycoproteins, and was neutralized by sera from HCV-infected patients and by some anti-E2 monoclonal antibodies. In addition, these pseudo-particles allowed investigation of the role of putative HCV receptors. Although our results tend to confirm their involvement, they provide evidence that neither LDLr nor CD81 is sufficient to mediate HCV cell entry. Altogether, these studies indicate that these pseudo-particles may mimic the early infection steps of parental HCV and will be suitable for the development of much needed new antiviral therapies.
Skip Nav Destination
Article navigation
3 March 2003
Article|
March 03 2003
Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
Birke Bartosch,
Birke Bartosch
1Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France
Search for other works by this author on:
Jean Dubuisson,
Jean Dubuisson
2Centre National de la Recherche Scientifique-UPR2511, Institut de Biologie de Lille, Institut Pasteur de Lille, 59021 Lille Cedex, France
Search for other works by this author on:
François-Loïc Cosset
François-Loïc Cosset
1Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France
Search for other works by this author on:
Birke Bartosch
1Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France
Jean Dubuisson
2Centre National de la Recherche Scientifique-UPR2511, Institut de Biologie de Lille, Institut Pasteur de Lille, 59021 Lille Cedex, France
François-Loïc Cosset
1Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France
Address correspondence to François-Loïc Cosset, LVRTG, ENS de Lyon, 46 Allée d'Italie, 69364 Lyon Cedex 07, France. Phone: 33-472-72-87-32; Fax: 33-472-72-80-80; E-mail: [email protected]
*
Abbreviations used in this paper: GFP, green fluorescent protein; HCV, hepatitis C virus; HCVpp, HCV pseudo-particles; LDLr, low density lipoprotein receptor; MLV, murine leukemia virus; PBMC, peripheral blood mononuclear cell; TU, transducing unit; VLDL, very low density lipoprotein.
Received:
October 03 2002
Revision Received:
January 03 2003
Accepted:
January 15 2003
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 197 (5): 633–642.
Article history
Received:
October 03 2002
Revision Received:
January 03 2003
Accepted:
January 15 2003
Citation
Birke Bartosch, Jean Dubuisson, François-Loïc Cosset; Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes . J Exp Med 3 March 2003; 197 (5): 633–642. doi: https://doi.org/10.1084/jem.20021756
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement